Question 1

Which GLP-1 schedule should I follow?

Accepted Answer

If you are prescribed a brand product (Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo), follow your prescriber's titration. The label schedules in this tool are the FDA-approved defaults for each product. Compounded injectable versions should be titrated under medical supervision.

Question 2

What is the standard Wegovy titration?

Accepted Answer

Wegovy uses a 16-week titration: 0.25 mg weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg as the maintenance dose. Many patients hold longer at lower doses depending on tolerance.

Question 3

What is the difference between Mounjaro and Zepbound?

Accepted Answer

Both contain tirzepatide as the active ingredient and share the same dose schedule. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for chronic weight management. Both titrate from 2.5 mg up to 15 mg by 2.5 mg every 4 weeks.

Question 4

What is Foundayo (orforglipron)?

Accepted Answer

Foundayo is the brand name for orforglipron, the first oral small-molecule GLP-1 receptor agonist approved by the FDA (April 1, 2026). It is approved for type 2 diabetes. Unlike injectable GLP-1 agents, it is a once-daily tablet taken with or without food. The titration schedule is: 2 mg daily for weeks 1–4, then 6 mg for weeks 5–8, then 12 mg maintenance from week 9 onward. The maximum approved dose is 12 mg per day.

Question 5

Is retatrutide FDA-approved?

Accepted Answer

No. Retatrutide is an investigational triple agonist (GLP-1 + GIP + glucagon) developed by Eli Lilly. The schedule shown reflects the Phase 2 trial titration. It is not approved for human use and should only be considered in a research context under physician guidance.

Question 6

How accurate are the volume and unit numbers for injectable protocols?

Accepted Answer

They are mathematically exact for the vial size and BAC water you enter. Real-world variation comes from vial overfill (typically 5–15%) and syringe dead-space. Always double-check your math.

Week	Weekly dose	Volume to draw	U-100 units
Week 1–4	0.25 mg	0.05 mL	5 units
Week 5–8	0.5 mg	0.1 mL	10 units
Week 9–12	1 mg	0.2 mL	20 units
Week 13–16	1.7 mg	0.34 mL	34 units
Week 17–20	2.4 mg	0.48 mL	48 units

Phase	Daily dose	Notes
Days 1–28 (Weeks 1–4)Active	2 mg	Starter dose, once daily
Days 29–56 (Weeks 5–8)	6 mg	Titration step, once daily
Day 57+ (Week 9+, maintenance)	12 mg	12 mg max; may remain at 6 mg if 12 mg not tolerated

Week	Weekly dose	Volume to draw	U-100 units
Week 1–4	0.25 mg	0.05 mL	5 units
Week 5–8	0.5 mg	0.1 mL	10 units
Week 9–12	1 mg	0.2 mL	20 units
Week 13–16	1.7 mg	0.34 mL	34 units
Week 17–20	2.4 mg	0.48 mL	48 units

Phase	Daily dose	Notes
Days 1–28 (Weeks 1–4)Active	2 mg	Starter dose, once daily
Days 29–56 (Weeks 5–8)	6 mg	Titration step, once daily
Day 57+ (Week 9+, maintenance)	12 mg	12 mg max; may remain at 6 mg if 12 mg not tolerated

GLP-1 Dose Escalator